Tilray Brands (TLRY) Gains from Investment Securities (2017 - 2025)
Tilray Brands (TLRY) reported Gains from Investment Securities of $4.6 million for Q4 2025, down 65.9% on a YoY basis from $13.3 million in Q4 2024, and up 691.59% quarter-over-quarter from $575000.0 in Q2 2025.
Tilray Brands (TLRY) Gains from Investment Securities (2017 - 2025) Analysis & Trends
Tilray Brands has reported Gains from Investment Securities for 9 years, with the latest figure at $4.6 million in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 65.9% year-over-year to $4.6 million; the trailing twelve-month figure through Feb 2026 stood at $1.4 million (down 84.79% YoY), and the FY2024 full-year result was $756615.0, up 1082.78% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $4.6 million, up from $575000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $19.7 million in Q2 2024, with the low at -$11.1 million in Q3 2023.
- Historically, Gains from Investment Securities has averaged $3.8 million across 5 years, with a median of $981229.0 in 2021.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities sank 14324.68% — and 2024, when it soared 3213.97%.
- Tilray Brands' Gains from Investment Securities stood at $845000.0 in 2021, then surged by 610.65% to $6.0 million in 2022, then gained by 26.0% to $7.6 million in 2023, then jumped by 76.39% to $13.3 million in 2024, then sank by 65.9% to $4.6 million in 2025.
- The last three Gains from Investment Securities figures came in at $4.6 million (Q4 2025), $575000.0 (Q2 2025), and $13.3 million (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Tilray Brands | - | - | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 4.55 Mn |
| Nov 30, 2025 | 4.55 Mn |
| May 31, 2025 | 575,000.00 |
| May 31, 2025 | 575,000.00 |
| Nov 30, 2024 | 13.35 Mn |
| Nov 30, 2024 | 13.35 Mn |
| Aug 31, 2024 | 862,000.00 |
| Aug 31, 2024 | 862,000.00 |
| May 31, 2024 | 19.69 Mn |
| May 31, 2024 | 19.69 Mn |
| Feb 29, 2024 | 11.67 Mn |
| Feb 29, 2024 | 11.67 Mn |
| Nov 30, 2023 | 7.57 Mn |
| Nov 30, 2023 | 7.57 Mn |
| Aug 31, 2023 | -11.11 Mn |
| Aug 31, 2023 | -11.11 Mn |
| May 31, 2023 | 6.10 Mn |
| May 31, 2023 | 6.10 Mn |
| Feb 28, 2023 | 352,000.00 |
| Feb 28, 2023 | 352,000.00 |